化疗对肺癌患者细胞免疫功能影响的研究

[目的]探讨化疗对各期肺癌患者治疗有效组及无效组细胞免疫功能的影响。[方法]用流式细胞仪检测58例受试者外周血T淋巴细胞亚群,NK细胞数目,辅助性T∕抑制性T比值(Th/Ts)。分别于初次化疗前1～2d及化疗2～3周期结束后10d测定。根据化疗疗效分为有效组与无效组,对比研究化疗后有效组及无效组患者细胞免疫功能的变化。[结果]化疗有效组患者39例,CD3+T细胞百分数在化疗前后比较差异无统计学意义(P﹥0.05),而CD4+T、CD8+CD28+T、NK细胞百分数及CD4+/CD8+比值在化疗后明显增加,差异有统计学意义(P﹤0.05);而CD8+T细胞在化疗后明显下降,差异有统计学意义(P﹤0.05);化疗无效组患者17例,CD3+T细胞在化疗前后变化差异无统计学意义(P﹤0.05),CD4+T细胞、CD8+CD28+T细胞、NK细胞在化疗后明显下降,差异有统计学意义(P﹤0.05),CD4+/CD8+比值有所下降,但差异无统计学意义(P﹤0.05),CD8+T细胞在化疗后显著增加,差异有统计学意义(P﹤0.05)。[结论]肺癌化疗有效组患者,免疫紊乱情况明显纠正,其本身的细胞免疫功能得到了提升;而化疗无效组患者,化疗后细胞免疫紊乱进一步加剧,免疫功能较化疗前继续恶化。

RESEARCH ON EFFECT OF CHEMOTHERAPY ON CELLULAR IMMUNITY OF PATIENTS WITH LUNG CANCER

[Objective]To investigate the effects of chemotherapy on cell immune function in patients with lung cancer between received remission and received no change/progression after chemotherapy.[Methods]The number of T lymphocyte subsets and natural killer cell and Th/Ts in 58 patients with lung cancer was measured with flow cytometry before primary chemotherapy and after 2-3 periods of chemotherapy.Patients with lung cancer were divided into 2 groups of receiving remission and receiving no change/progression bas...